 <h1>Fingolimod Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of fingolimod include:</b> infection, back pain, diarrhea, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, and increased liver enzymes. <b>Other side effects include:</b> blurred vision, bradycardia, bronchitis, increased gamma-glutamyl transferase, lymphocytopenia, migraine, dizziness, dyspnea, hypertension, increased serum transaminases, and tinea.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to fingolimod: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, fingolimod may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking fingolimod:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>chills</li>
<li>cough</li>
<li>cough-producing mucus</li>
<li>diarrhea</li>
<li>difficult or labored breathing</li>
<li>dizziness</li>
<li>fever</li>
<li>general feeling of discomfort or illness</li>
<li>headache</li>
<li>joint pain</li>
<li>loss of appetite</li>
<li>muscle aches and pains</li>
<li>nausea</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>runny nose</li>
<li>seizures</li>
<li>shivering</li>
<li>slow or fast heartbeat</li>
<li>sore throat</li>
<li>sweating</li>
<li>tightness in the chest</li>
<li>trouble sleeping</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>chest pain or discomfort</li>
<li>headache, severe and throbbing</li>
<li>hoarseness</li>
<li>lightheadedness, dizziness, or fainting</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>unusual bleeding or bruising</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>back pain</li>
<li>change in size, shape, or color of existing mole</li>
<li>confusion</li>
<li>difficulty in moving</li>
<li>difficulty in speaking</li>
<li>double vision</li>
<li>drowsiness</li>
<li>epileptic seizure that will not stop</li>
<li>hives, itching, skin rash</li>
<li>inability to move the arms, legs, or facial muscles</li>
<li>inability to speak</li>
<li>irritability</li>
<li>joint stiffness or swelling</li>
<li>loss of consciousness</li>
<li>mole that leaks fluid or bleeds</li>
<li>mood or mental changes</li>
<li>muscle pain, cramps, or stiffness</li>
<li>new mole</li>
<li>redness of the skin</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>slow speech</li>
<li>stiff neck</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>troubled swallowing</li>
<li>weight loss</li>
<li>yellow skin and eyes</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of fingolimod may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Pain or tenderness around the eyes and cheekbones</li>
<li>stuffy nose</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Decreased weight</li>
<li>depression</li>
<li>eye pain</li>
<li>hair loss or thinning of the hair</li>
<li>itching in the genitals or other skin areas</li>
<li>lack or loss of strength</li>
<li>scaling</li>
<li>stomach pain</li>
<li>skin rash, encrusted, scaly, and oozing</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fingolimod: oral capsule</i></p><h3>General</h3><p>The most common adverse events were headache, influenza, diarrhea, back pain, liver transaminase elevations, and cough.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, first degree AV block, bradycardia </p>
<p><b>Uncommon</b> (0.1% to 1%): Symptomatic bradycardia, second degree AV block</p>
<p><b>Rare</b> (0.01% to 0.1%): Peripheral arterial occlusive disease</p>
<p><b>Very rare</b> (less than 0.01%): Hemophagocytic syndrome </p>
<p><b>Frequency not reported</b>: Heart rate decrease, Mobitz type I (Wenckebach) block, Mobitz type II block</p>
<p><b>Postmarketing reports</b>: Third degree AV block, AV block with junctional escape, transient asystole, peripheral arterial occlusive disease<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): ALT/AST increased (14%)</p>
<p><b>Common</b> (1% to 10%): Elevation in liver transaminases, GGT increased, hepatic enzyme increased, liver function test abnormal<sup>[Ref]</sup></p><p>In the majority of cases, elevations in liver enzymes occurred within 6 to 9 months and returned to normal within approximately 2 months following discontinuation of fingolimod.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Influenza viral infection (13%), sinusitis (10.9%), infections</p>
<p><b>Common</b> (1% to 10%): Herpes viral infection, bronchitis, gastroenteritis, tinea infection </p>
<p><b>Uncommon</b> (0.1% to 1%): Pneumonia</p>
<p><b>Frequency not reported</b>: Fatal herpetic infection, fatal varicella zoster virus infection<sup>[Ref]</sup></p><p>Infections occurred at a rate similar to placebo.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Symptoms of posterior reversible encephalopathy syndrome included sudden onset of severe headache, altered mental status, visual disturbances, and seizure.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (25%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, paresthesia, migraine </p>
<p><b>Rare</b> (less than 0.1%): Posterior reversible encephalopathy syndrome, ischemic and hemorrhagic stroke </p>
<p><b>Frequency not reported</b>: Neurological atypical disorders</p>
<p><b>Postmarketing reports</b>: Syncope<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (12%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Lymphopenia, leukopenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Neutrophil count decreased<sup>[Ref]</sup></p><h3>Ocular</h3><p>Macular edema occurred at a dramatically higher rate in patients with a history of uveitis.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Vision blurred, eye pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Macular edema<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (10%)</p>
<p><b>Common</b> (1% to 10%): Dyspnea, reduction in diffusion lung capacity, reduction in FEV1<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (12%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia, eczema, pruritus<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Weight decreased, blood triglycerides increased<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia </p>
<p><b>Postmarketing reports</b>: Unexplained death<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression</p>
<p><b>Uncommon</b> (0.1% to 1%): Depressed mood<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Lymphoma<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Rash, urticaria, angioedema</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Gilenya (fingolimod)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What are the new drugs used for multiple sclerosis (MS)?</li>
<li>Gilenya vs Tecfidera. How do they compare?</li>
<li>What happens when you stop taking Gilenya?</li>
<li>How long does it take Gilenya to work?</li>
<li>Does Gilenya suppress the immune system?</li>
<li>Does Gilenya cause hair loss?</li>
<li>How much does Gilenya cost?</li>
<li>Where is Gilenya manufactured and by whom?</li>
<li>What does Gilenya do for multiple sclerosis (MS)?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about fingolimod</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>92 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
<li>FDA Alerts (4)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Fingolimod &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Gilenya</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Sclerosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fingolimod: oral capsule</i></p><h3>General</h3><p>The most common adverse events were headache, influenza, diarrhea, back pain, liver transaminase elevations, and cough.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, first degree AV block, bradycardia </p><p><b>Uncommon</b> (0.1% to 1%): Symptomatic bradycardia, second degree AV block</p><p><b>Rare</b> (0.01% to 0.1%): Peripheral arterial occlusive disease</p><p><b>Very rare</b> (less than 0.01%): Hemophagocytic syndrome </p><p><b>Frequency not reported</b>: Heart rate decrease, Mobitz type I (Wenckebach) block, Mobitz type II block</p><p><b>Postmarketing reports</b>: Third degree AV block, AV block with junctional escape, transient asystole, peripheral arterial occlusive disease<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): ALT/AST increased (14%)</p><p><b>Common</b> (1% to 10%): Elevation in liver transaminases, GGT increased, hepatic enzyme increased, liver function test abnormal<sup>[Ref]</sup></p><p>In the majority of cases, elevations in liver enzymes occurred within 6 to 9 months and returned to normal within approximately 2 months following discontinuation of fingolimod.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Influenza viral infection (13%), sinusitis (10.9%), infections</p><p><b>Common</b> (1% to 10%): Herpes viral infection, bronchitis, gastroenteritis, tinea infection </p><p><b>Uncommon</b> (0.1% to 1%): Pneumonia</p><p><b>Frequency not reported</b>: Fatal herpetic infection, fatal varicella zoster virus infection<sup>[Ref]</sup></p><p>Infections occurred at a rate similar to placebo.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Symptoms of posterior reversible encephalopathy syndrome included sudden onset of severe headache, altered mental status, visual disturbances, and seizure.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (25%)</p><p><b>Common</b> (1% to 10%): Dizziness, paresthesia, migraine </p><p><b>Rare</b> (less than 0.1%): Posterior reversible encephalopathy syndrome, ischemic and hemorrhagic stroke </p><p><b>Frequency not reported</b>: Neurological atypical disorders</p><p><b>Postmarketing reports</b>: Syncope<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (12%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Lymphopenia, leukopenia</p><p><b>Uncommon</b> (0.1% to 1%): Neutrophil count decreased<sup>[Ref]</sup></p><h3>Ocular</h3><p>Macular edema occurred at a dramatically higher rate in patients with a history of uveitis.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Vision blurred, eye pain</p><p><b>Uncommon</b> (0.1% to 1%): Macular edema<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (10%)</p><p><b>Common</b> (1% to 10%): Dyspnea, reduction in diffusion lung capacity, reduction in FEV1<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (12%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia, eczema, pruritus<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Weight decreased, blood triglycerides increased<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia </p><p><b>Postmarketing reports</b>: Unexplained death<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression</p><p><b>Uncommon</b> (0.1% to 1%): Depressed mood<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Lymphoma<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Rash, urticaria, angioedema</p><p id="ref_1">1. "Product Information. Gilenya (fingolimod)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the new drugs used for multiple sclerosis (MS)?</li>
<li>Gilenya vs Tecfidera. How do they compare?</li>
<li>What happens when you stop taking Gilenya?</li>
<li>How long does it take Gilenya to work?</li>
<li>Does Gilenya suppress the immune system?</li>
<li>Does Gilenya cause hair loss?</li>
<li>How much does Gilenya cost?</li>
<li>Where is Gilenya manufactured and by whom?</li>
<li>What does Gilenya do for multiple sclerosis (MS)?</li>
</ul><h2>More about fingolimod</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>92 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
<li>FDA Alerts (4)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Fingolimod &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Sclerosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>